Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Supernus Pharm
(NQ:
SUPN
)
30.83
+0.56 (+1.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Supernus Pharm
< Previous
1
2
3
4
Next >
Supernus Provides Regulatory Update on SPN-830
October 10, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Top Medical Specialties Stocks: Trading Opportunities For Next Week - Sunday, Oct. 2
October 02, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Here is a closer look at some medical stock opportunities...
Via
Talk Markets
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients
May 02, 2022
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Stocks That Made New Highs On Friday, Aug. 19
August 21, 2022
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs.
Via
Talk Markets
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
July 25, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
May 01, 2022
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...
Via
Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
April 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
Looking Into Supernus Pharmaceuticals's Return On Invested Capital
April 14, 2022
According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million.
Via
Benzinga
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
April 07, 2022
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.
Via
Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
February 21, 2022
Supernus Pharmaceuticals shares soared 5.7% in the last trading session to close at $32.90. The move was backed by solid volume with far more shares changing hands than in a normal session.
Via
Talk Markets
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
January 24, 2022
Via
AB Newswire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript
November 04, 2021
SUPN earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Supernus Pharmaceuticals: Q3 Earnings Insights
November 03, 2021
Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Why Supernus' Acquisition of Adamas Is a Smart Move
October 21, 2021
Adamas looks like a good fit for Supernus.
Via
The Motley Fool
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
October 11, 2021
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For November 3, 2021
November 03, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
October 11, 2021
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
October 11, 2021
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
October 11, 2021
ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million.
Via
InvestorPlace
Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights
October 11, 2021
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal...
Via
Benzinga
Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization
August 16, 2021
Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What...
Via
Benzinga
Exposures
COVID-19
Supernus Pharmaceuticals, inc (SUPN) Q2 2021 Earnings Call Transcript
August 04, 2021
SUPN earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.